腫瘤學英文編修樣本

Leiomyosarcoma (LMS) 1 areis a rare tumors of small intestinal tumore, which arises from the musculalris mucosa or muscularis propria and mainly occurs in the 6th decade of life, with slight male preponderance. The most common site of occurrence of LMS in the small intestine is the jejunum, followed by the ileum and then duodenum. The Its common presentations manifestations include abdominal mass, abdominal pain, and or overt gastrointestinal bleeding. .They are mainly seen in 6th decade of life with slight male preponderance. In general, the Ppreoperative diagnosis of small intestinal tumors such as LMSs is difficult, especially in terms of differentiating between benign and malignant tumors. For LMS in small intestine, According to a recent review of literature review, revealed that computed tomography (CT)- and magnetic resonance (MRI)- enterography and enteroclysis are good optionsmodalities for the assessment of LMS. Cases of sSuperficial lesions, which  2 can be missed by both CT and MRI imaging, can however be detected by water capsule endoscopy, with a detection rate of around approximately 80%. Histologically, LMS resembles like gastrointestinal stromal tumorGIST, 3 ; however, on immunohistochemical analysis, it has been found to be negative for they are CD117 and CD34 negative by immunohistochemistry and positive for smooth muscle antigen actin (SMA) and desmin. When the size of LMS these tumors are is more than 5 cm, they it commonly spread can hematogenously spread to the liver (65%), other gastrointestinalGI organs (15%), and the lungs (4%). It also has the capability tocan also spread via the lymphatics system (13%) or via peritoneal route (18%). The only effective treatment for small intestine LMS is surgery. The primary tumor should be excised radically, including a wide resection of the mesentry. The Rresponse of LMS to chemotherapy is doubtfulunknown,, and there is no role for radiotherapy does not play a role in treatment.  Therefore, surgery is the only effective treatment for LMS in the small intestine. The primary tumor should be excised radically, with wide resection of the mesentery  4 . If possible, Therefore, mmetastasectomy, if possible, should be considered.  Large phase II and III studies trials involving the combination of combining docetaxel and gemcitabine have reported yielded impressive response rates for in LMSs (mostly of uterine origin). However, some studies others were have not been able to confirm the efficacy of this combination. Recently, tTrabectedin has recently showed response rates of up to 56% for in LMSs, and it has appeared to be especially particularly useful against in far-advanced and metastatic LMSs after failure of the combination of anthracyclines and ifosfamide combination therapy.